Krabbe Disease
2
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Forge BiologicsOH - Grove City
3 programs2
FBX-101Phase 1/21 trial
FBX-101Phase 1/21 trial
FBX-101N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Forge BiologicsFBX-101
Forge BiologicsFBX-101
Forge BiologicsFBX-101
CENTOGENEBiomarker for Krabbe Disease (BioKrabbe)
Clinical Trials (4)
Total enrollment: 17 patients across 4 trials
Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Treated Previously With HSCT
Start: Feb 2023Est. completion: Nov 20269 patients
Phase 1/2Active Not Recruiting
Gene Transfer Clinical Trial for Krabbe Disease
Start: Nov 2021Est. completion: Nov 20266 patients
Phase 1/2Active Not Recruiting
Long-term Follow-up Study to Evaluate Safety and Efficacy of FBX-101 in Krabbe Patients
Start: Aug 2024Est. completion: Apr 20252 patients
N/ATerminated
Biomarker for Krabbe Disease (BioKrabbe)
Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space